Inflammatory Myopathies and Dermatomyositis
Research Guide

Bohan and Peter (1975) defined criteria including characteristic skin rash for dermatomyositis, symmetrical proximal muscle weakness, elevated serum muscle enzymes such as creatine phosphokinase, electromyographic findings, and muscle biopsy evidence. These criteria classify definite, probable, and possible disease based on the number met. Laboratory features like enzyme elevation support diagnosis and monitor treatment response.

Lundberg et al. (2017) in the 2017 European League Against Rheumatism/American College of Rheumatology criteria classify adult and juvenile idiopathic inflammatory myopathies and subgroups based on clinical and laboratory features. These criteria address limitations in prior systems for early and limited disease. They incorporate myositis-specific antibodies and improve diagnostic accuracy.

Interstitial lung disease frequently accompanies inflammatory myopathies like dermatomyositis as a comorbidity. Distler et al. (2019) showed nintedanib lowers the annual forced vital capacity decline rate in systemic sclerosis-associated cases versus placebo. This supports antifibrotic treatment strategies in myopathy-related lung involvement.

Autoantibodies and myositis-specific antibodies are central to classification and clinical features in dermatomyositis and polymyositis. The field discusses their links to interstitial lung disease and cancer risk. Bohan and Peter (1975) noted shared features with connective-tissue diseases involving autoantibodies.

van den Hoogen et al. (2013) updated classification criteria for systemic sclerosis, which overlap with polymyositis/dermatomyositis in multicenter studies comparing early cases. These criteria enhance sensitivity for limited cutaneous forms and early disease. Masi (1980) provided preliminary criteria distinguishing systemic sclerosis from polymyositis/dermatomyositis.